The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

ACS analysis of cancer mortality by congressional district finds decreased death rate in men and women, persistent racial disparities

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Researchers at the American Cancer Society, in an analysis of cancer death rates across all congressional districts in the U.S., found an overall decline in the past 25 years, with most districts showing a 20%-45% decline among males and a 10%-40% decline among females. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Medicaid expansion may improve cancer care and survival for people with HR-negative, HER2-positive breast cancer

New research published in the Journal of the National Comprehensive Cancer Network found that people with newly-diagnosed hormone receptor-negative, human epidermal growth factor receptor 2-positive breast cancer were more likely to receive timely, guideline-concordant treatment, and have longer survival in states that participate in Medicaid expansion under the Affordable Care Act.
Clinical Roundup

Vulnerable patients have a decreased mortality risk when treated at CoC-accredited hospitals, ACS study says

Vulnerable patients facing social, environmental, and economic disadvantages often experience worse cancer outcomes than other groups. Some of these disparities may be reduced by increasing access to hospitals accredited by the American College of Surgeons Commission on Cancer, according to a study published in the Journal of the American College of Surgeons.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account